SCHEMBL6876004

SCHEMBL6876004

O=C1c2ccc(-c3ccc(CN4CC(=O)N(CC5CC5)C4=O)cc3)cc2CN1CC(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
ENPP2 Q13822 2/20 0.35
HRH3 Q9Y5N1 4/20 0.34
JAK2 O60674 5/20 0.34
JAK1 P23458 5/20 0.34
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
ACHE P22303 1/20 0.33
HDAC6 Q9UBN7 2/20 0.32
KCNH2 Q12809 1/20 0.32
HDAC2 Q92769 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1814937 0.87 HDAC1 (0.39) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL6873688 0.85 HDAC1 (0.38) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL1820132 0.84 ENPP2 (0.48) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL6874779 0.83 ENPP2 (0.38) HDAC1HDAC8ENPP2HDAC6HDAC2
SCHEMBL1817499 0.83 ENPP2 (0.37) HDAC1HDAC8ENPP2HRH3HDAC6
SCHEMBL1819817 0.83 HDAC4 (0.40) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL12004090 0.80 HDAC6 (0.42) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL1816290 0.79 MAPK1 (0.39) HDAC1HDAC4ENPP2HRH3ACHE
SCHEMBL12003977 0.79 HDAC4 (0.41) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL6875401 0.78 PPARG (0.37) HDAC1HDAC4ENPP2HRH3PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507521-B2 Heterocyclic derivatives Merck Sharp + Dohme B.V. (NL) 2013-08-13 US disclosed
US-8507521-B2 Heterocyclic derivatives Merck Sharp + Dohme B.V. (NL) 2013-08-13 US disclosed
US-8507521-B2 Heterocyclic derivatives Merck Sharp + Dohme B.V. (NL) 2013-08-13 US disclosed
US-20120220622-A1 HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-08-30 US disclosed
US-20120220622-A1 HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-08-30 US disclosed
US-20120220622-A1 HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-08-30 US disclosed
WO-2011051490-A2 HETEROCYCLIC DERIVATIVES N.V. ORGANON (NL) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220622-A1 HETEROCYCLIC DERIVATIVES GRIN2C, GRIN3A, GRIN2D HDAC1 698/4885HDAC8 1236/4885HDAC3 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.